The combined treatment with chloroquine and the enzymatic oxidation products of spermine overcomes multidrug resistance of melanoma M14 ADR2 cells: A new therapeutic approach

  • Authors:
    • Enzo Agostinelli
    • Maria Condello
    • Giampiero Tempera
    • Alberto Macone
    • Giuseppina Bozzuto
    • Shinji Ohkubo
    • Annarica Calcabrini
    • Giuseppe Arancia
    • Agnese Molinari
  • View Affiliations

  • Published online on: June 18, 2014     https://doi.org/10.3892/ijo.2014.2502
  • Pages: 1109-1122
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

It has been confirmed that multidrug resistant (MDR) melanoma cells (M14 ADR2) are more sensitive than their wild-type counterparts (M14 WT) to H2O2 and aldehydes, the products of bovine serum amine oxidase (BSAO)-catalyzed oxidation of spermine. The metabolites formed by BSAO and spermine are more toxic, in M14 cells, than exogenous H2O2 and acrolein, even though their concentration is lower during the initial phase of incubation due to their more gradual release than the exogenous products. Binding of BSAO to the cell membrane and release of the reaction products of spermine into the immediate vicinity of the cells, or directly into the cells, may explain the apparently paradoxical phenomenon. Both WT and MDR cells, after pre-treatment for 24 h, or longer, with the lysosomotropic compound chloroquine (CQ), show to be sensitized to subsequent exposure to BSAO/spermine enzymatic system. Evidence of ultrastructural aberrations and acridine orange release from lysosomes is presented in this study that is in favor of the permeabilization of the lysosomal membrane as the major cause of sensitization by CQ. Pre-treatment with CQ amplifies the ability of the metabolites formed from spermine by oxidative deamination to induce cell death. Melanocytes, differently from melanoma cells, were unaffected by the enzymatic system, even when preceded by CQ treatment. Since it is conceivable that combined treatment with a lysosomotropic compound and BSAO/spermine would be effective against tumour cells, it is of interest to search for such novel compounds, which might be promising for application in a therapeutic setting.
View Figures
View References

Related Articles

Journal Cover

September-2014
Volume 45 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Agostinelli E, Condello M, Tempera G, Macone A, Bozzuto G, Ohkubo S, Calcabrini A, Arancia G and Molinari A: The combined treatment with chloroquine and the enzymatic oxidation products of spermine overcomes multidrug resistance of melanoma M14 ADR2 cells: A new therapeutic approach. Int J Oncol 45: 1109-1122, 2014.
APA
Agostinelli, E., Condello, M., Tempera, G., Macone, A., Bozzuto, G., Ohkubo, S. ... Molinari, A. (2014). The combined treatment with chloroquine and the enzymatic oxidation products of spermine overcomes multidrug resistance of melanoma M14 ADR2 cells: A new therapeutic approach. International Journal of Oncology, 45, 1109-1122. https://doi.org/10.3892/ijo.2014.2502
MLA
Agostinelli, E., Condello, M., Tempera, G., Macone, A., Bozzuto, G., Ohkubo, S., Calcabrini, A., Arancia, G., Molinari, A."The combined treatment with chloroquine and the enzymatic oxidation products of spermine overcomes multidrug resistance of melanoma M14 ADR2 cells: A new therapeutic approach". International Journal of Oncology 45.3 (2014): 1109-1122.
Chicago
Agostinelli, E., Condello, M., Tempera, G., Macone, A., Bozzuto, G., Ohkubo, S., Calcabrini, A., Arancia, G., Molinari, A."The combined treatment with chloroquine and the enzymatic oxidation products of spermine overcomes multidrug resistance of melanoma M14 ADR2 cells: A new therapeutic approach". International Journal of Oncology 45, no. 3 (2014): 1109-1122. https://doi.org/10.3892/ijo.2014.2502